Skip to main content
Clinical Trials/NCT02793921
NCT02793921
Completed
Not Applicable

Influence of Exercise on Neurocognitive Function in Breast Cancer

University of Pittsburgh1 site in 1 country153 target enrollmentApril 2016
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
University of Pittsburgh
Enrollment
153
Locations
1
Primary Endpoint
Change in Cognitive Function
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This randomized control trial will examine whether a well-controlled and monitored exercise intervention improves cognitive function in postmenopausal women with early-stage breast cancer and will explore whether neuroimaging metrics of brain health, pro-inflammatory biomarkers and symptoms (fatigue, sleep problems, depression, anxiety) mediate the effects of exercise on cognitive function. Furthermore, the study will explore whether the magnitude of the improvements in cognitive function are modified by estradiol levels.

Detailed Description

The specific aims include: 1. Compared to usual care, examine whether the 6-month exercise intervention improves cognitive function in postmenopausal women with early stage breast cancer. Hypothesis 1. Exercise will improve cognitive function in women in a domain specific fashion such that attention, executive and memory functions will be influenced more than other domains. 2. Compared to usual care, examine the direct effects of exercise on neuroimaging metrics of brain health including regional gray matter volume, white matter architecture and functional dynamics of the brain and the pro-inflammatory biomarkers (IL-6 as primary outcomes; TNF-α as secondary), and explore the direct effects of exercise on symptoms (fatigue, sleep problems, depression, anxiety). Hypothesis 2. Exercise will improve neuroimaging metrics of brain health and pro-inflammatory biomarkers. 3. Compared to usual care, explore whether the effects of exercise on cognitive function are mediated by a) neuroimaging metrics of cognitive function, b) IL-6 and TNF-α levels and c) symptoms (fatigue, sleep problems, depression, anxiety), and moderated by E2 levels.

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
January 10, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Catherine M. Bender, PhD, RN, FAAN

Professor

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Postmenopausal female
  • Maximum age 80 years
  • Able to speak and read English
  • Minimum completion of 8 years of education
  • Diagnosed with Stage 0, 1, 2 or 3a Breast Cancer
  • Within 2 years post-completion of primary treatment
  • At least two weeks post-breast conserving surgery or three weeks post-breast conserving surgery with sentinel lymph node biopsy or four weeks post-mastectomy

Exclusion Criteria

  • Prior treatment with cancer chemotherapy, central nervous system radiation, or intrathecal therapy
  • Clinical evidence of distant metastases
  • Self-report of hospitalization for psychiatric illness within the last two years
  • History of neurologic illness
  • Any of the following breast cancer surgery complications unless approved by the participant's health care provider: persistent seroma requiring aspiration, wound dehiscence, infection, prolonged drain output, lymphedema
  • Reconstructive surgery unless approved by the participant's health care provider
  • Any significant medical condition that would preclude them from exercising (e.g., uncontrolled diabetes, congestive heart failure, angina, uncontrolled arrhythmia or other symptoms that indicate increased risk for an acute cardiovascular or respiratory event) If necessary, we will verify this information with a participant's health care provider
  • Eating disorders or a history of substance abuse
  • Any use of an assisted walking device
  • Recent history of falls or balance problems

Outcomes

Primary Outcomes

Change in Cognitive Function

Time Frame: Baseline to 6 months

Cognitive function was assessed with a battery of 14 measures. A data reduction technique, exploratory factor analysis with principal component extraction and varimax (orthogonal) rotation, was used to create summary factors. The cognitive factors identified included processing speed, attention, mental flexibility, working memory, learning and memory, verbal memory, and executive function were derived via this factor analysis. Individual measures with the highest loadings were included in each factor. All measures had factor loadings \>0.400. Scores from the individual measures for each factor were normed based on healthy controls of similar age and education to yield a z-score and these were summed to yield an average z-score for each factor. Z-scores range from -4 to +4, where higher z-scores indicate better performance for each factor.

Secondary Outcomes

  • Fatigue(Baseline and 6 months)
  • Sleep Problems(Baseline to 6 months)
  • Pro-inflammatory Cytokines(Baseline to 6 months)
  • Peak VO2(Baseline and 6 months)
  • Anxiety(Baseline to 6 months)
  • Depressive Symptoms(Baseline to 6 months)
  • Total Brain Size(Baseline and 6 months)
  • Estradiol (E2) Levels(Baseline to 6 months)

Study Sites (1)

Loading locations...

Similar Trials